Skip to content
OpenCapital
Get started

Arbutus Biopharma Corporation ABUS EV / sales

EV / sales at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
14×+10.9×
Gilead Sciences logo
Gilead SciencesGILD
6.3×+0.9×
ALN
Alnylam PharmaceuticalsALNY
9.9×-4.7×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
5.8×+1.4×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-127.1×-128×
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
19×-10.6×

Other financials

Income statement

See full
Revenue$179.1M+10,055%
Operating income$168.9M+757%
Net income$169.7M+792%
EPS (diluted)$0.87+769%

Balance sheet

See full
Cash & equivalents$23.7M-36.1%
Total debt$631.0K-46.9%
Total equity$260.2M+229%
Total assets$277.2M+137%

Cash flow

See full
Operating cash flow-$8.1M+39.4%
CapEx--100%
Free cash flow-$4.7M+55.0%

Valuation

See full
Market cap$881.02M+32.6%
Enterprise value$857.94M+36.6%
P/E5.5×—
P/S4.6×-99.1×

Profitability

See full
Operating margin81.7%+42.1pp
Net margin84%+43.4pp
FCF margin-281.5%-119pp

Returns & leverage

See full
Return on equity94.7%+65.1pp
Debt / equity0×0.0×
Current ratio54.3×+48.3×

Where this comes from

Calculated from Arbutus Biopharma Corporation’s reported figures.

enterprise value/total revenue=4.5×

Based on the most recent quarter.

The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arbutus Biopharma Corporation's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arbutus Biopharma Corporation's EV / sales?
Arbutus Biopharma Corporation (ABUS) reported EV / sales of 4.5× in Q1 2026.
How has Arbutus Biopharma Corporation's EV / sales changed year-over-year?
Arbutus Biopharma Corporation's EV / sales decreased by 95.5% year-over-year, from 98.8× to 4.5×.
What is the long-term trend for Arbutus Biopharma Corporation's EV / sales?
Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's EV / sales has grown at a 0.7% compound annual growth rate (CAGR), from 62.3× to 64.5×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.